Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Nuvectis Pharma, Inc.NVCT · Entity 5166 | Director | June 11, 2026 | June 12, 2026 |
| TG THERAPEUTICS, INC.TGTX · Entity 3608 | Director | June 11, 2026 | June 15, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Nuvectis Pharma, Inc.
Report date June 11, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 168,140 |
Reported balance
After 2026-06-11 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 35,000 · Balance 168,140 F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates. F2: Includes shares of restricted common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: The 35,000 shares of restricted common stock will vest in equal annual installments over three years beginning on the first anniversary of the grant date subject to Mr. Hoberman's continued service on the Company's Board of Directors on such dates.
F2: Includes shares of restricted common stock.
TG THERAPEUTICS, INC.
Report date June 11, 2026 · Filed June 15, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Tracking UnitSEC Table II · derivative / convertible security | Direct | 8,325 |
Reported balance
After 2026-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-11 · Grant · Acquired 8,325 · Balance 8,325 F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant. F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Each stock tracking unit ("STU") represents a contingent right to receive either (determined at the sole discretion of the committee of the Board of Directors of the Issuer that administers the Issuer's 2022 Incentive Plan) (i) one share of the Issuer's common stock or (ii) a cash payment equal to the fair market value of one share of the Issuer's common stock, no later than thirty (30) days after the first anniversary of the date of grant.
F2: Provided the Reporting Person remains in continuous service with the Issuer through the vesting date, the STUs shall vest upon the first anniversary of the date of grant.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
STEMLINE THERAPEUTICS INC
Report date June 10, 2020 · Filed June 10, 2020
Section 16 reporting ended · disclosed 2020-06-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2020-06-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2020-06-10 · Grant · Acquired 600,000 · Balance 1,374,352 F1: Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement"). Row 2 · 2020-06-10 · Other · Disposed 1,374,352 · Balance 0 F2: Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.77 · Expires 2026-01-07 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-06-10 · Disposition to issuer · Disposed 25,000 · Balance 0 F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3: All options were vested and exercisable as of the effective time of the merger. |
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.12 · Expires 2026-02-24 | Direct | 0 |
Reported balance
After 2020-06-10 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-06-10 · Disposition to issuer · Disposed 44,058 · Balance 0 F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option. F3: All options were vested and exercisable as of the effective time of the merger. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents previously-granted performance-based awards that became vested under the agreement and plan of merger among Issuer, Berlin-Chemie AG, and Mercury Merger Sub, Inc., dated as of May 3, 2020 (the "Merger Agreement").
F2: Disposed of in connection with a tender offer made pursuant to the Merger Agreement, in exchange for $11.50 per share, net to the holder in cash, plus one contractual contingent value right ("CVR") per share (collectively, the "Offer Price"). Each CVR represents the right to receive a payment of $1.00 in cash upon the achievement of a certain milestone relating to the first sale of ELZONRIS in any one of certain countries following a marketing authorization approval by the European Commission. The CVR milestone must be achieved on or prior to December 31, 2021.
F3: All options were vested and exercisable as of the effective time of the merger.
F4: Disposed of under the Merger Agreement in exchange for the excess of the Offer Price over the exercise price of the option.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 12, 2018 Filed Mar 14, 2018 21:30 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 13,942 | $17.18 | $239,523.56 |
DisclosureSEC source: 0001104659-18-017586 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 425,639 F1 · shares: In connection with the vesting of 32,868 shares on March 9, 2018, a total of 13,942 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $16.70 to $17.70. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 425,639 shares, 293,990 shares are restricted stock. Read SEC document |
| March 08, 2018 Filed Mar 9, 2018 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 70,303 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-18-016434 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 439,581 F4 · shares: The 70,303 restricted shares will vest in four installments as follows: 17,576 shares on March 8, 2019; 17,576 shares on March 8, 2020; 17,576 shares on March 8, 2021; and 17,575 shares on March 8, 2022. F5 · balance_after: Of the 439,581 shares, 326,858 shares are restricted stock. Read SEC document |
| March 07, 2018 Filed Mar 9, 2018 21:32 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 3,027 | $16.55 | $50,096.85 |
DisclosureSEC source: 0001104659-18-016434 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 369,278 F1 · shares: In connection with the vesting of 6,095 shares on March 6, 2018, a total of 3,027 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $16.35 to $16.85. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 369,278 shares, 256,555 shares are restricted stock. Read SEC document |
| February 27, 2018 Filed Feb 28, 2018 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 5,726 | $17.26 | $98,830.76 |
DisclosureSEC source: 0001104659-18-013695 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 371,915 F1 · shares: In connection with the vesting of 21,996 shares on February 24, 2018, a total of 11,026 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F4 · price: Reflects the weighted average sale price. The range of prices for such transaction is $16.95 to $17.45. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F5 · balance_after: Of the 371,915 shares, 262,650 shares are restricted stock. Read SEC document |
| February 26, 2018 Filed Feb 28, 2018 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 5,300 | $17.61 | $93,333.00 |
DisclosureSEC source: 0001104659-18-013695 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 377,641 F1 · shares: In connection with the vesting of 21,996 shares on February 24, 2018, a total of 11,026 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $17.60 to $17.75. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 377,641 shares, 262,650 shares are restricted stock. Read SEC document |
| February 15, 2018 Filed Feb 16, 2018 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 1,851 | $15.67 | $29,005.17 |
DisclosureSEC source: 0001104659-18-010450 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 382,941 F1 · shares: In connection with the vesting of 3,746 shares on February 14, 2018, a total of 1,851 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $15.60 to $15.83. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 382,941 shares, 284,646 shares are restricted stock. Read SEC document |
| January 08, 2018 Filed Jan 12, 2018 21:31 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 14,040 | $13.93 | $195,577.20 |
DisclosureSEC source: 0001104659-18-002137 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 384,792 F1 · shares: In connection with the vesting of 25,000 shares on January 8, 2018, a total of 14,040 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $13.70 to $14.05. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 384,792 shares, 288,392 shares are restricted stock. Read SEC document |
| December 18, 2017 Filed Dec 19, 2017 19:58 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 40 | $14.75 | $590.00 |
DisclosureSEC source: 0001104659-17-074139 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,832 F1 · shares: In connection with the vesting of 25,000 shares on November 29, 2017, a total of 11,983 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F4 · balance_after: Of the 398,832 shares, 313,392 shares are restricted stock. Read SEC document |
| December 15, 2017 Filed Dec 19, 2017 19:58 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 11,943 | $14.18 | $169,351.74 |
DisclosureSEC source: 0001104659-17-074139 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 398,872 F1 · shares: In connection with the vesting of 25,000 shares on November 29, 2017, a total of 11,983 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $14.08 to $14.43. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 398,872 shares, 313,392 shares are restricted stock. Read SEC document |
| June 16, 2017 Filed Jun 19, 2017 22:10 UTC | TG THERAPEUTICS, INC. TGTX · Entity 3608 | GrantCOMMON STOCK | 15,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001654954-17-005706 · section16.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,905 F1 · kind: Reflects a grant of restricted shares that will vest on June 16, 2020. F2 · balance_after: Includes shares of restricted Common Stock, which vest over various time periods Read SEC document |
| March 09, 2017 Filed Mar 9, 2017 21:33 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | GrantCommon Stock | 131,469 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-17-015592 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,143 F4 · shares: The 131,469 restricted shares will vest in four installments as follows: 32,868 shares on March 9, 2018; 32,867 shares on March 9, 2019; 32,867 shares on March 9, 2020; and 32,867 shares on March 9, 2021. F5 · balance_after: Of the 409,143 shares, 338,392 shares are restricted stock. Read SEC document |
| March 07, 2017 Filed Mar 9, 2017 21:33 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 2,342 | $8.16 | $19,110.72 |
DisclosureSEC source: 0001104659-17-015592 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 277,674 F1 · shares: In connection with the vesting of 6,095 shares on March 6, 2017, a total of 2,342 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $8.10 to $8.18. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 277,674 shares, 206,923 shares are restricted stock. Read SEC document |
| February 28, 2017 Filed Mar 1, 2017 21:53 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 4,027 | $7.01 | $28,229.27 |
DisclosureSEC source: 0001104659-17-013194 · a4.xml · nonDerivative · entry 2 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 279,655 F1 · shares: In connection with the vesting of 21,997 shares on February 24, 2017, a total of 8,027 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F4 · price: Reflects the weighted average sale price. The range of prices for such transaction is $6.85 to $7.20. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F5 · balance_after: Of the 279,655 shares, 213,018 shares are restricted stock. Read SEC document |
| February 27, 2017 Filed Mar 1, 2017 21:53 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 4,000 | $6.97 | $27,880.00 |
DisclosureSEC source: 0001104659-17-013194 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 283,682 F1 · shares: In connection with the vesting of 21,997 shares on February 24, 2017, a total of 8,027 of such shares were sold by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such sale, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $6.90 to $7.03. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 283,682 shares, 213,018 shares are restricted stock. Read SEC document |
| February 16, 2017 Filed Feb 17, 2017 21:03 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 1,508 | $6.42 | $9,681.36 |
DisclosureSEC source: 0001104659-17-010293 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 287,682 F1 · shares: In connection with the vesting of 3,746 shares on February 14, 2017, a total of 1,508 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such action, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $6.35 to $6.50. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 287,682 shares, 235,015 shares are restricted stock. Read SEC document |
| January 10, 2017 Filed Jan 13, 2017 20:01 UTC | STEMLINE THERAPEUTICS INC STML · Entity 148550 | SaleCommon Stock | 9,110 | $13.82 | $125,900.20 |
DisclosureSEC source: 0001104659-17-002351 · a4.xml · nonDerivative · entry 1 Hoberman Kenneth · CIK 0001573722 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 289,190 F1 · shares: In connection with the vesting of 25,000 shares on January 7, 2017, a total of 9,110 of such shares were withheld by the Company in order to satisfy the reporting person's tax withholding obligations. The reporting person had no discretion with respect to such action, which was conducted automatically in accordance with the issuer's corporate policies. F2 · price: Reflects the weighted average sale price. The range of prices for such transaction is $13.68 to $13.90. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. F3 · balance_after: Of the 289,190 shares, 238,761 shares are restricted stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.